Search

Allogeneic processed thymus tissue

[A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric … Allogeneic processed thymus tissue is used for immune reconstitution in immune disorders where the patients are severely immunocompromised due to the absence of a functional thymus, such as congenital

Chromium gluconate

Chromium nicotinate

Terfenadine

In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.

Elranatamab

[L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437] … It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one

Nemolizumab

[A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169] … [L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis.

Human botulinum neurotoxin A/B immune globulin

[L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism. … Infant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut.

Metharbital

Metharbital is a barbiturate anticonvulsant, similar to phenobarbital, marketed as Gemonil by Abbott Laboratories. It was patented in 1905 by Emil Fischer of Merck.

Alfacalcidol

In Canada, it is marketed as ONE-ALPHA, which manages hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in adults with chronic renal failure. … [A234044] It plays an essential function in calcium homeostasis and bone metabolism.

Human C1-esterase inhibitor

[L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction … The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.[L16586, L16606]